Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Muscle Invasive Bladder Cancer

Sponsor: Bristol-Myers Squibb

Sponsor score: 60

ClinicalTrials ID:NCT03661320

This clinical trial is testing whether adding the drug nivolumab, or a combination of nivolumab and BMS-986205, to standard chemotherapy before surgery can improve treatment outcomes for adults with muscle-invasive bladder cancer. The study also looks at continuing these treatments after surgery.

Patient Parameters

Program Overview

The aim of this study is to see if adding the immunotherapy drug nivolumab, or a combination of nivolumab and BMS-986205, to the standard chemotherapy treatment of gemcitabine and cisplatin (GC) before surgery can help treat muscle-invasive bladder cancer more effectively. After surgery, participants will continue with either nivolumab alone or the combination of nivolumab and BMS-986205 to see if it helps prevent the cancer from returning.

Eligibility Criteria

Inclusion Criteria

  • Must be eligible for a surgery called Radical Cystectomy, as determined by your cancer doctor or urologist, and agree to have this surgery after completing the initial treatment.
  • Must be in good overall health, with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.

Exclusion Criteria

  • Cannot have evidence of cancer spread to lymph nodes or other parts of the body.
  • Cannot have had previous treatments like chemotherapy, radiation, or surgery for bladder cancer, except for a procedure called transurethral resection of bladder tumor (TURBT) or biopsies.

Locations

FACILITYZIPCITYSTATE
Local Institution - 002285711TucsonArizona
UC Davis Comprehensive Cancer Center95817SacramentoCalifornia
Local Institution - 002180120-4413LittletonColorado
Local Institution - 003632503PensacolaFlorida
Local Institution - 000433612TampaFlorida
Local Institution - 014430342AtlantaGeorgia
Local Institution - 000560637ChicagoIllinois
Local Institution - 000661615PeoriaIllinois
Local Institution - 018121044ColumbiaMaryland
Local Institution - 000902114BostonMassachusetts

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.